BusinessWire Feed
Tanner Health and Mercer University School of Medicine Celebrate Opening of Carrollton Clinical Campus and Simulation Lab
CARROLLTON, Ga.--(BUSINESS WIRE)--The Carrollton community and leaders from across the state of Georgia gathered at Tanner Medical Center/Carrollton on Friday, July 17, to celebrate the opening of Tanner Health and Mercer University School of Medicine more...
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio Both INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated more...
UF Health Lung Transplant Program Earns Top Marks for Patient Outcomes
GAINESVILLE, Fla.--(BUSINESS WIRE)--The UF Health lung transplant program has again been recognized by the Scientific Registry of Transplant Recipients, or SRTR, for outstanding patient outcomes, reinforcing its reputation as a premier choice for patients seeking more...
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
Noble Africa was created to unlock the value of Renergen's Virginia Gas Project through a public company focused on helium and LNG Learn why the Virginia Gas Project is positioned to become one of the more...
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society more...
Colgate-Palmolive Webcasts 2026 Second Quarter Earnings Conference Call July 31, 2026 – 8:30 a.m. ET
NEW YORK--(BUSINESS WIRE)--Colgate-Palmolive Company (NYSE:CL) will provide a live webcast of its 2026 second quarter earnings conference call on Friday, July 31, 2026, at 8:30 a.m. ET. The call will be hosted by Chairman, President more...
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose ---- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 --PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), more...
Inflammasome Therapeutics Reports Positive Six-Month Phase 2 Results for K8 in Geographic Atrophy
0.7 mg cohort showed a 54% lower mean rate of geographic atrophy (GA) growth (slope) than control eyes; a prespecified extrafoveal analysis showed an adjusted 4.0-letter mean BCVA advantage for K8 versus control – both more...
Sun Nuclear to Showcase Next-Generation Innovations at AAPM & COMP 2026 Annual Meeting
Daily QA™ 4 Pro for streamlined daily machine quality assurance Plan AI™ for treatment planning and AdaptCHECK™ for online adaptive therapy verification Clinical presentations and product demonstrations throughout the meeting in Sun Nuclear Booth 800 more...
Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
Henry Ford Health selected as one of only four U.S. academic health systems in Bayer’s strategic research networkDETROIT--(BUSINESS WIRE)--Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand more...
Medifast® Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health System
The leading health and wellness company unveils an evolutionary transformation from weight loss to optimal metabolic health, powered by breakthrough science and human connectionBALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced the launch of Trilivy, a more...
Planet DDS Declares the Practice Management Era Over and Launches DentalOS®, the Dental Enterprise Platform for DSOs
One Patient. One Schedule. One RCM.IRVINE, Calif.--(BUSINESS WIRE)--Planet DDS today declared the practice management era in dental software over and launched DentalOS®, the dental enterprise platform built to replace it. DentalOS is not a smarter more...
Ardent Health Announces Second Quarter 2026 Results Conference Call and Webcast Date
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its second quarter 2026 results after the market closes on more...
Aptar Pharma Launches Integrated System-Level Framework to Support Injectable Drug Development
Combines partner collaboration, system-level testing and performance data packages to support earlier development decisions and help address evolving USP <382> expectationsCRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and more...
Weave Launches Authorized Integration with Elation Health, Significantly Reducing Manual Workflows for Primary Care Practices
80% of Healthcare Staff Spend at Least 30 Minutes a Day on Manual Data Entry — New Integration Gives That Time Back to Primary Care TeamsLEHI, Utah--(BUSINESS WIRE)--#getweave--Weave (NYSE: WEAV), a leading AI-powered patient engagement more...
ThalassaX Therapeutics Announces First Patient Dosed in U.S. Phase I Trial of CS231295, a Brain-Penetrant Aurora B Kinase Selective Inhibitor
SOMERSET, N.J.--(BUSINESS WIRE)--#AI--ThalassaX Therapeutics United States Ltd today announced that the first patient has been successfully dosed in the U.S. Phase I clinical trial of CS231295, a next-generation brain-penetrant Aurora B Kinase selective inhibitor independently more...
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 more...
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
SAN CARLOS, Calif.--(BUSINESS WIRE)--$ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the financial markets open. more...
American Junior Investigator Association (AJIA) – America’s Got Research Celebrates Next Generation Scientific Innovators at Inaugural National Competition
AJIA unites academia, industry, and venture capital to honor emerging leaders in medicine and biotechnologyNEW YORK--(BUSINESS WIRE)--More than 200 leaders from academia, biotechnology, venture capital, and patient advocacy gathered at the Yale Club of New more...
AHF Expands to Kyiv With Its Second HIV Clinic in Ukraine
The organization now serves more than 98,000 clients across Ukraine as it scales up services during wartime conditionsKYIV, Ukraine--(BUSINESS WIRE)--#AIDS--AIDS Healthcare Foundation (AHF) Ukraine has opened the first Test & Treat Clinic for HIV in more...
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
Surveillance coverage significantly strengthened with new LCD across kidney, heart, and lung transplantation, expanding coverage for Prospera testing across critical post-transplant settingsAUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision more...
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost more...
Mirador Therapeutics Expands Precision Immunology Portfolio with Exclusive License to KP-301, a Long-Acting Anti-C5a Antibody
Agreement with Kira Pharmaceuticals for exclusive license to KP-301 extends Mirador’s precision medicine strategy into inflammatory vascular disease, with an initial focus on ANCA-associated vasculitis (AAV)KP-301 is engineered to inhibit C5a/C5aR-mediated inflammation through an antibody more...
Aptar Declares Quarterly Dividend
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that the Board declared a quarterly cash dividend of $0.48 per share. more...
FCPT Closes Acquisition of 102 Mission Pet Health Veterinary Properties for $268 Million as part of Previously Announced Mission Pet Health Veterinary Transaction
MILL VALLEY, Calif.--(BUSINESS WIRE)--Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties (“FCPT” or the “Company”), closed on the purchase more...